Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Elzonris (tagraxofusp-erzs)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Menarini, Nippon Shinyaku

Drug class:

CD123 inhibitor, IL-3 antagonist, Elongation factor 2 inhibitor

Related drugs:

TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	venetoclax + tagraxofusp-erzs Sensitive: C3 – Early Trials venetoclax + tagraxofusp-erzs Sensitive : C3	venetoclax + tagraxofusp-erzs Sensitive: C3 – Early Trials venetoclax + tagraxofusp-erzs Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	tagraxofusp-erzs Sensitive: C3 – Early Trials tagraxofusp-erzs Sensitive : C3	tagraxofusp-erzs Sensitive: C3 – Early Trials tagraxofusp-erzs Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + tagraxofusp-erzs Sensitive: C3 – Early Trials venetoclax + tagraxofusp-erzs Sensitive : C3	venetoclax + tagraxofusp-erzs Sensitive: C3 – Early Trials venetoclax + tagraxofusp-erzs Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	tagraxofusp-erzs Sensitive: C3 – Early Trials tagraxofusp-erzs Sensitive : C3	tagraxofusp-erzs Sensitive: C3 – Early Trials tagraxofusp-erzs Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	tagraxofusp-erzs Sensitive: D – Preclinical tagraxofusp-erzs Sensitive : D	tagraxofusp-erzs Sensitive: D – Preclinical tagraxofusp-erzs Sensitive : D